Now Available as an E-Book!
Amyloid Beta Peptides as Biomarkers of Subconcussion
Aries Biotech is pleased to share that a recent publication is now available within the Frontiers - Insights in Neurotrauma: 2021 E-Book.
Increased levels of circulating amyloid beta (abeta) - 40 and -42 peptides are often increased after concussion. As such, these peptides are promising blood biomarkers of post-concussive events and neurological damage. Concussion-like symptoms are also associated with increased abeta in peripheral blood after blast exposure devoid of a clinically defined injury. A recently published review and opinion article highlights recent work describing Abeta elevation in peripheral blood among persons with probable or diagnosed concussion. The authors propose utility of abeta to augment clinical examination or provide rationale for continuous, post-event monitoring.
These studies were originally featured in
Frontiers Neurology, Neurotrauma - Insights in Neurotrauma: 2021 Online
“Opinion: The Potential Role of Amyloid Beta Peptides as Biomarkers of Subconcussion and Concussion”
Angela M Boutté, Ph.D., Bharani Thangavelu, Ph.D., and John Anagli, Ph.D.
https://www.frontiersin.org/articles/10.3389/fneur.2022.941151/full
To view the Insights in Neurotrauma: 2021 Topic Homepage, visit
https://www.frontiersin.org/research-topics/27889/insights-in-neurotrauma-2021
Aries Biotech is a neurological disease and dementia biomarker consulting company that provides guidance, data interpretation, and document review for hypothesis-driven research.
To learn how we can augment your research, visit Aries Biotech at https://www.ariesbiotechnologies.org